Expert Review of Anticancer Therapy, Год журнала: 2025, Номер unknown
Опубликована: Апрель 11, 2025
Язык: Английский
Biomedicines, Год журнала: 2025, Номер 13(2), С. 422 - 422
Опубликована: Фев. 10, 2025
The intricate relationship between anticancer drugs and the gut microbiome influences cancer treatment outcomes. This review paper focuses on role of integrity in enhancing efficacy safety drug therapy, emphasizing pharmacokinetic interactions microbiota. It explores how disruptions to composition, or dysbiosis, can alter metabolism, immune responses, side effects. By examining mechanisms disruption caused by drugs, this highlights specific case studies like cyclophosphamide, 5-fluorouracil, irinotecan, their impact microbial diversity clinical also discusses microbiome-targeted strategies, including prebiotics, probiotics, postbiotics, fecal microbiota transplantation (FMT), as promising interventions enhance treatment. Furthermore, potential profiling personalizing therapy integrating these into practice is explored. Finally, proposes future research directions, developing novel biomarkers a deeper comprehension drug-microbiome interactions, respond current gaps knowledge improve patient outcomes care.
Язык: Английский
Процитировано
1
Discover Oncology, Год журнала: 2025, Номер 16(1)
Опубликована: Фев. 19, 2025
Although previous observational studies have highlighted a possible association between the gut microbiota (GM) and head neck cancer (HNC), causal relationships remain unclear, particularly regarding role of plasma proteins as potential mediators. Clarifying these connections is essential for uncovering underlying mechanisms HNC progression may lead to new therapeutic strategies. First, we examined link GM via two-sample Mendelian randomization (MR) approach. We then investigated causative same MR technique. The coefficient product approach was used clarify in pathway HNC. Finally, sensitivity investigations were performed assess robustness coherence results. analyses revealed protective effects one family six genera on (Lachnospiraceae, Parabacteroides, Phascolarctobacterium, Alistipes, Sutterella, Roseburia Alloprevotella). In contrast, three (Ruminococcus, Prevotella Bacteroides) significantly positively associated with risk. Through further examination, researchers discovered 18 that relationship Notably, mediation illustrated effect OTU97_86 (Phascolarctobacterium) (total IVW: OR = 0.879, 95% 0.810–0.954, p 0.002) mediated by Proteasome subunit alpha type-1 (PSMA1) (− 0.020, CI − 0.039 ~ 0.001, 0.036), accounting 15.25% total effect. Similarly, OTU99_35 (Ruminococcus) risk 1.109, 1.027–1.198, 0.008) protein FAM107B (0.015, 0.001–0.029, 0.031), 14.69% analysis specific GMs influence through proteins: Phascolarctobacterium protects against PSMA1, whereas Ruminococcus increases FAM107B. These pathways suggest preventative factor factor. This highlights possibility using biomarkers or targets prevention, diagnosis, treatment.
Язык: Английский
Процитировано
0
Frontiers in Physiology, Год журнала: 2025, Номер 16
Опубликована: Март 19, 2025
In recent years, the study of gut microbiota has gradually become a research hotspot in field medicine, as dysbiosis is closely related to various diseases. Thalassemia, hereditary hemoglobinopathy, complex pathophysiological mechanism, and traditional treatment methods show limited efficacy. With deeper understanding microbiome, researchers have begun focus on its role pathogenesis thalassemia therapeutic effects. This article aims review potential prospects, analyze latest findings, explore impact mechanisms patients with thalassemia, goal providing new ideas directions for future clinical thalassemia.
Язык: Английский
Процитировано
0
Expert Review of Anticancer Therapy, Год журнала: 2025, Номер unknown
Опубликована: Апрель 11, 2025
Язык: Английский
Процитировано
0